Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Intraosseous Injection of Flurbiprofen Axetil for Postoperative Analgesia in Joint Arthroplasty

18. november 2026 oppdatert av: Hua Luo, Taizhou Hospital

This single-center, prospective, randomized, double-blind, double-dummy controlled trial aims to evaluate the efficacy and safety of intraosseous versus intravenous flurbiprofen axetil for postoperative pain management in patients undergoing joint arthroplasty.

A total of 240 patients aged 65-80 years undergoing primary unilateral total knee arthroplasty, unicompartmental knee arthroplasty, total hip arthroplasty, or hemiarthroplasty will be enrolled. Participants will be stratified according to surgical procedure and randomly assigned in a 1:1 ratio to receive either intraosseous flurbiprofen axetil with intravenous saline placebo or intravenous flurbiprofen axetil with intraosseous saline placebo. The dose of flurbiprofen axetil will be 50 mg in both groups.

The primary outcome is postoperative pain intensity at rest, assessed using the Visual Analog Scale (VAS) at predefined time points from 1 hour to 6 weeks after surgery. Secondary outcomes include pain during movement, cumulative opioid consumption within 72 hours, length of hospital stay, joint functional recovery, patient satisfaction, patient-controlled analgesia utilization, and adverse events.

This study aims to determine whether intraosseous administration of flurbiprofen axetil provides effective and safe postoperative analgesia compared with conventional intravenous administration following joint arthroplasty.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

240

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Zhejiang
      • Linhai, Zhejiang, Kina, 317000
        • Rekruttering
        • No. 150 Ximen Road
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

65 år til 80 år (Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Adults aged 65 to 80 years, regardless of sex.
  • Patients scheduled to undergo unilateral joint arthroplasty.
  • Patients scheduled for elective surgery with standardized surgical procedures and prosthesis types, consistent with the postoperative analgesia protocol of this study.
  • Patients scheduled to receive general anesthesia.
  • Patients who are able to understand the study objectives, procedures, and potential risks, voluntarily provide written informed consent, and cooperate with postoperative assessments, including Visual Analog Scale (VAS) pain scores, functional assessments, and patient satisfaction evaluations.

Exclusion Criteria:

  • Known hypersensitivity to flurbiprofen, other nonsteroidal anti-inflammatory drugs (NSAIDs), or contraindications to opioids or other medications used in the study.
  • Contraindications to NSAID use, including peptic ulcer disease, gastrointestinal bleeding, severe hepatic or renal impairment, or coagulation disorders.
  • Severe cardiovascular, hepatic, renal, hematological, or central nervous system diseases that may prevent patients from tolerating general anesthesia or analgesic medications.
  • Recent history of gastrointestinal bleeding or active peptic ulcer disease.
  • Severe infection, immunodeficiency, or risk of sepsis.
  • Psychiatric disorders or cognitive impairment that prevent reliable assessment of postoperative pain intensity or patient satisfaction.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Intraosseous Flurbiprofen

Participants will receive a total dose of 50 mg flurbiprofen axetil via intraosseous administration.

For knee arthroplasty, the medication will be administered into the distal femoral and proximal tibial bone cavities. For hip arthroplasty, the medication will be administered into the bone cavity near the greater trochanter.

Flurbiprofen axetil 50 mg will be administered intraosseously into the distal femoral and proximal tibial bone cavities for knee arthroplasty or near the greater trochanter for hip arthroplasty.

Flurbiprofen axetil 50 mg will be administered intravenously.

Aktiv komparator: Intravenous Flurbiprofen Axetil

Participants will receive 50 mg flurbiprofen axetil through intravenous administration.

Flurbiprofen axetil 50 mg will be administered intraosseously into the distal femoral and proximal tibial bone cavities for knee arthroplasty or near the greater trochanter for hip arthroplasty.

Flurbiprofen axetil 50 mg will be administered intravenously.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Visual Analog Scale
Tidsramme: At 1, 2, 3, 4, 5, 6, 12, 24, 48, and 72 hours after surgery; postoperative day 7; and postoperative weeks 2 and 6.

Postoperative pain intensity at rest will be assessed using the Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity.

At 1, 2, 3, 4, 5, 6, 12, 24, 48, and 72 hours after surgery; postoperative day 7; and postoperative weeks 2 and 6.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Cumulative Opioid Consumption Within 72 Hours
Tidsramme: up to 72 hours post-surgery

The cumulative dose of opioid analgesics administered during the first 72 hours after surgery will be recorded. Opioid consumption will be converted into morphine milligram equivalents to facilitate comparison between the two treatment groups.

up to 72 hours post-surgery
Length of Hospital Stay
Tidsramme: From the date of hospital admission to the date of hospital discharge, assessed up to 30 days.

The length of hospital stay will be calculated as the number of days from hospital admission to hospital discharge. The duration of hospitalization will be compared between the two treatment groups. Unit: days.

From the date of hospital admission to the date of hospital discharge, assessed up to 30 days.
Knee Society Score
Tidsramme: At baseline (preoperative assessment), postoperative days 1, 3, and 7, and postoperative weeks 2 and 6.

Postoperative knee function will be evaluated using the Knee Society Score (KSS). Scores are recorded at predefined postoperative time points and compared between the two treatment groups to assess functional recovery. Unit: score.

At baseline (preoperative assessment), postoperative days 1, 3, and 7, and postoperative weeks 2 and 6.
Patient Satisfaction With Postoperative Analgesia
Tidsramme: At hospital discharge.

Patient satisfaction with postoperative analgesia will be assessed using a 10-point Numerical Rating Scale (NRS), ranging from 0 (completely dissatisfied) to 10 (completely satisfied). Higher scores indicate greater satisfaction. Unit: score.

At hospital discharge.
Cumulative PCA Analgesic Consumption
Tidsramme: From PCA initiation to PCA discontinuation, within the first 72 hours after surgery.

The cumulative amount of analgesic medication delivered through the patient-controlled analgesia (PCA) system will be recorded from PCA initiation until discontinuation. The total medication consumption will be expressed in milligrams (mg), and the duration of PCA use will also be recorded. Unit: mg.

From PCA initiation to PCA discontinuation, within the first 72 hours after surgery.
Incidence of Adverse Events
Tidsramme: up to 3 months post-surgery

The incidence of adverse events will be assessed in both treatment groups. Recorded events will include gastrointestinal bleeding, renal impairment, cardiovascular events, and wound infection ect.

up to 3 months post-surgery

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

31. desember 2025

Primær fullføring (Faktiske)

1. april 2026

Studiet fullført (Antatt)

30. april 2027

Datoer for studieregistrering

Først innsendt

23. oktober 2026

Først innsendt som oppfylte QC-kriteriene

18. november 2026

Først lagt ut (Faktiske)

20. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

20. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

18. november 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • K20251066

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere